New York, Apr 15 (EFE News). The Pfizer Pharmaceutical Delegate, Albert Bourla, has “probably” needed a third dose of vaccine refraction against covid-19 inside the two months after he had been completely vaccinated, for which he was vaccinated. complete.
“It’s extremely important to override the group of people who can be susceptible to the virus,” Bourla told the CNBC television channel in a statement stating these juveniles.
The executor also indicated that these doses would be an important remedy to shed light on the variants of the covid he demonstrated most contagiously.
At the moment, it is being discontinued for some time to protect the vacancies against covid-19, given the shortcomings of this product.
Pfizer recently announced that its vaccine against covid-19 has increased by 91% against the virus and more than 95% against the worst symptoms of the disease and that this protection is maintained for less than six months after haber received the first dose.
Asimismo, the people who received the vaccine against the covid-19 of Moderna, whose composition is similar to that of Pfizer, themselves showing high levels of anticoagulation six months after the second dose, according to a study published in the scientific journal The New England Journal of Medicine a principios de mes.
The study revealed by Pfizer shows that its vacancy seems to work in a similar way to the majority of viruses in South Africa, one of the countries where the product is being tested.
Pfizer Pharmaceuticals announced on February 26 that it was studying the possibility of injecting a third dose into people evacuated in order to strengthen the protection against the more aggressive coronavirus variants.
Bourla insures that with this third dose it will force the response of the anticoagulants between 10 and 20 weeks and suppose that, as long as the person is vaccinated annually against the flu, he or she will have to do against the covid-19 to be protected.
This new studio is run by two edad groups, people between 65 and 85 years old and comprised between 18 and 55 years old and will be elected by the group that participated in the first high school graduates in the field of Pfizer and BioNTech pharmaceuticals. .
The University of Oxford has initiated a new clinical study to determine whether it is possible to combine doses of the vacancies and obtain an immunological response adequate with the manufacturer’s independent dose.
The investigators are involved in the participation of the AstraZeneca, Pfizer, Moderna and the candidate of the Novavax stadium candidate.
(c) EFE Agency